Vitestro Secures $70 Million Series B to Scale Autonomous Robotic Blood Collection Technology Globally
Netherlands — Vitestro, a pioneering medical robotics company focused on automating diagnostic blood collection, announced today the closing of a $70 million Series B financing. The funding will accelerate the development and global deployment of the company's autonomous robotic phlebotomy device and establish a new standard in venous access procedures.
Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of venipuncture procedures performed annually in hospitals, clinics, and laboratories worldwide. Despite its frequency, the procedure has seen little technological innovation for decades. Vitestro aims to change this by introducing AI-powered robotics that can consistently and safely draw blood without human intervention.
Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection, said Toon Overbeeke, Chief Executive Officer and co-founder of Vitestro.
The company's vision aligns with the broader trend of applying autonomous systems to laboratory operations. Similar to how Lila Sciences is building autonomous AI laboratories, Vitestro is bringing automation to diagnostic procedures.
Funding Overview
The Series B financing was raised from a distinguished group of strategic healthcare investors, financial institutions, and existing backers, demonstrating broad confidence in Vitestro's technology and commercial potential.
Leading the round were new strategic and healthcare investors including Labcorp Venture Fund, Mayo Clinic, and Sutter Health — three of the most respected names in diagnostic laboratory services and healthcare delivery. Their participation reflects recognition of Vitestro's potential to transform a foundational healthcare procedure.
Additional new investors included InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht, along with existing investors including Invest-NL (supported by InvestEU), EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital.
The $70 million financing represents the largest European investment in medical robotics for diagnostic procedures this year and positions Vitestro for rapid commercial expansion.
Addressing a Fundamental Healthcare Challenge
Venipuncture — the process of drawing blood from a vein — is performed billions of times annually worldwide. Despite its frequency, the procedure faces significant challenges that impact healthcare systems globally:
Phlebotomy staffing shortages represent a critical constraint as healthcare systems struggle to recruit and retain skilled phlebotomists. The Bureau of Labor Statistics projects that demand for phlebotomists in the United States will grow 17% through 2032, but supply is not keeping pace with demand.
Variable needle insertion technique leads to inconsistent success rates and patient discomfort. Studies suggest that first-attempt venipuncture success rates vary widely, from 50-95%, depending on patient factors and operator experience.
Patient safety concerns include needlestick injuries affecting healthcare workers and the risk of improper sample collection leading to inaccurate test results. The Centers for Disease Control and Prevention estimates that approximately 385,000 needlestick injuries occur annually in the United States healthcare sector.
Operational inefficiency results in delays that impact patient throughput, laboratory processing, and healthcare costs. Blood collection failures require repeat draws, consuming additional resources and extending patient wait times.
Traditional approaches to addressing these challenges have focused on training and process improvements, but technological innovation has been limited. Vitestro's solution represents a fundamentally new approach to an ancient medical procedure.
The Technology: Aletta Autonomous Robotic Phlebotomy Device
Aletta, Vitestro's autonomous robotic phlebotomy device (ARPD), represents a breakthrough in medical robotics. The system integrates multiple advanced technologies to safely and consistently perform venous access procedures:
A multimodal imaging system utilizes near-infrared spectroscopy, ultrasound, and visible light imaging to identify suitable veins in real-time. This enables the robot to visualize veins that may not be visible to the human eye, particularly in patients with difficult venous access.
Artificial intelligence algorithms analyze the imaging data to assess vein quality, depth, and suitability for cannulation. The AI has been trained on datasets encompassing millions of venous assessments, enabling robust prediction of successful cannulation sites.
Precision robotics provide sub-millimeter needle placement accuracy, far exceeding human capabilities. The robotic system can precisely target the vein wall and achieve optimal insertion depth on the first attempt.
Adaptive feedback mechanisms adjust the procedure in real-time based on resistance and flow characteristics, ensuring successful blood collection while minimizing patient discomfort.
The entire procedure requires minimal human intervention. The patient places their arm in the device, and Aletta autonomously performs vein identification, needle insertion, blood collection, and needle withdrawal. The process typically requires fewer than five minutes from start to finish.
The integration of AI and robotics mirrors the approach taken by companies like Weave Bio in applying AI to regulatory workflows — using technology to automate complex processes that traditionally required significant human expertise.
Clinical Evidence and Regulatory Path
Vitestro has accumulated substantial clinical evidence supporting the safety and efficacy of its technology. Multiple clinical studies conducted in European healthcare settings have demonstrated:
First-attempt success rates exceeding 95%, significantly above typical healthcare facility averages.
Patient satisfaction scores higher than conventional phlebotomy, with patients citing reduced anxiety and discomfort.
Sample quality matching or exceeding standard manual collection, with hemolysis rates below industry averages.
The company is pursuing regulatory clearance through the FDA De Novo classification pathway, which provides a regulatory pathway for novel medical devices. Regulatory submissions are supported by the extensive European clinical data and strategic partnerships with major U.S. healthcare systems.
The involvement of Mayo Clinic and Sutter Health as investors reflects their belief in the regulatory pathway and commercial potential. These health systems will likely become early adopters upon FDA clearance.
Market Opportunity
The global market for diagnostic blood collection exceeds $50 billion annually, encompassing laboratory services, hospital phlebotomy, and outpatient collection. The addressable market for automated phlebotomy solutions includes:
Hospitals and health systems performing hundreds of millions of venipuncture procedures annually represent the largest market segment. Labor costs for phlebotomy represent a significant portion of laboratory budgets, making automation economically compelling.
Standalone diagnostic laboratories, including Quest Diagnostics, Laboratory Corporation of America, and regional players, perform high volumes of routine blood collection. Automation could reduce per-procedure costs while improving consistency.
Specialty clinics and research facilities require reliable blood collection for clinical trials and specialized testing. Automated phlebotomy could improve protocol compliance and reduce variability.
The United States represents the largest single market opportunity, but international expansion will drive significant additional growth. Healthcare systems in Europe and Asia face similar staffing pressures and are seeking solutions.
Commercialization Strategy
Vitestro has developed a comprehensive commercialization strategy to bring Aletta to the global healthcare market:
The initial focus will be on European markets, where regulatory clearance has already been achieved in key markets. The company will establish relationships with major healthcare systems and diagnostic laboratory networks.
U.S. market entry will follow FDA De Novo clearance, with launch through strategic partnerships with major laboratory service providers. Mayo Clinic and Sutter Health, as investors, are likely to become early adopters.
The company plans to offer both capital purchase and subscription-based pricing models, accommodating different customer preferences and financial situations. This flexibility could accelerate adoption across varied healthcare settings.
Customer support and field service infrastructure will be established in key markets, ensuring that customers receive comprehensive implementation and ongoing support.
Value Proposition for Healthcare Systems
Vitestro's technology delivers compelling value proposition across multiple stakeholder groups:
For healthcare administrators, the system offers reduced labor costs, improved operational consistency, and decreased needlestick injury liability. The return on investment calculations suggest payback within 2-3 years depending on volume.
For phlebotomists and nursing staff, Aletta reduces repetitive strain injuries and frees staff to focus on higher-value patient interactions. Rather than performing routine venipuncture, staff can concentrate on complicated collections and patient education.
For patients, the system provides reduced anxiety and discomfort, more consistent experience, and faster service. Patient satisfaction scores in European deployments have exceeded conventional approaches.
For laboratories, improved sample quality reduces repeat draws and associated costs. Consistent venipuncture technique also improves testing accuracy and reliability.
Competitive Landscape
While Vitestro is pioneering autonomous robotic phlebotomy, the company competes with several categories of solutions:
Traditional phlebotomy equipment manufacturers, including Becton Dickinson, Greiner Bio-One, and Terumo, provide improved needles and collection sets but require human operators. These solutions cannot address the staffing constraint.
Vein visualization device companies, including Accuvein and Veneprobe, improve vein identification but do not automate the insertion process. Some facilities use these devices alongside conventional methods.
Other medical robotics companies are pursuing automated solutions but are at earlier stages of development. Some universities and startups are conducting research in this space, but Vitestro maintains a significant lead.
Labcorp Venture Fund sees strong potential in solutions that modernize core diagnostic processes and improving consistency for patients. Applying robotics, multimodal imaging, and AI to clinically validated diagnostic blood collection is an exciting approach, and we're thrilled to support Vitestro as they advance this important work, said Megann Vaughn Watters, Head of Labcorp Venture Fund.
Investor Perspective
The Series B financing reflects exceptional investor enthusiasm for a company that has demonstrated technical validation, clinical evidence, and commercial potential. Several factors distinguish Vitestro:
Strong market timing aligns with healthcare system needs for operational efficiency and labor solutions. Post-pandemic staffing challenges have increased urgency for automation.
Strategic investor involvement provides both financial support and commercial credibility. Labcorp, Mayo Clinic, and Sutter Health bring unmatched domain expertise and potential for early adoption.
Demonstrated technical achievement distinguishes Vitestro from concept-stage competitors. The company has functioning devices in clinical use — far ahead of theoretical approaches.
Large and growing market opportunity provides room for substantial value creation. The diagnostic blood collection market continues to expand as screening and disease management become more prevalent.
Looking Ahead
With the completion of this $70 million Series B, Vitestro enters an ambitious expansion phase. The company must execute across multiple dimensions:
Technical refinement will continue to improve device performance, reliability, and ease of use based on real-world feedback. The investment will support ongoing engineering and software development.
Regulatory clearance in the United States represents a critical milestone. The company must complete its FDA De Novo submission and achieve clearance to access the largest market.
Commercial infrastructure must be established in anticipation of broader market access. This includes sales, service, and customer success organizations in key markets.
Manufacturing scale-up will enable production volumes necessary for commercial deployment. Quality systems and supply chain development are priorities.
If successful, Vitestro could transform a fundamental healthcare procedure that has remained essentially unchanged for centuries. The combination of AI, robotics, and medical technology positions the company to define a new category in diagnostic medicine.
The biotechnology and medical technology industries will watch closely as Vitestro advances toward global commercialization.